Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:haloperidol
|
| gptkbp:affiliatedWith |
typical antipsychotic
|
| gptkbp:ATCCode |
N05AD01
|
| gptkbp:contraindication |
gptkb:Parkinson's_disease
hypersensitivity to haloperidol |
| gptkbp:discoveredIn |
1958
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:marketedIn |
various countries
|
| gptkbp:routeOfAdministration |
oral
intramuscular injection |
| gptkbp:sideEffect |
restlessness
drowsiness extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia |
| gptkbp:usedFor |
schizophrenia
psychosis Tourette syndrome acute psychotic states severe agitation |
| gptkbp:bfsParent |
gptkb:haloperidol
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Haloperil
|